Market capitalization | $61.80m |
Enterprise Value | $68.37m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 19.71 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-57.85m |
Free Cash Flow (TTM) Free Cash Flow | $-45.97m |
Cash position | $31.40m |
As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.
8 Analysts have issued a Rani Therapeutics Holdings Inc - Ordinary Shares Class A forecast:
8 Analysts have issued a Rani Therapeutics Holdings Inc - Ordinary Shares Class A forecast:
Jun '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -1.21 -1.21 |
27%
27%
|
|
EBITDA | -57 -57 |
15%
15%
|
EBIT (Operating Income) EBIT | -58 -58 |
16%
16%
|
Net Profit | -31 -31 |
11%
11%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Rani Therapeutics Holdings, Inc. operates as a clinical stage bio-therapeutics company providing technologies to enable the development of orally administered biologics. It offers RaniPill capsule, an orally ingestible pill for the administration of a broad range of biologics. The company was founded by Mir Imran on April 6, 2021 and is headquartered in San Jose, CA.
Head office | United States |
CEO | Talat Imran |
Employees | 140 |
Founded | 2012 |
Website | www.ranitherapeutics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.